Loading
companiesCompany
SpringWorks Therapeutics (Merck KGaA)
SpringWorks developed nirogacestat, the first approved treatment for desmoid tumours, and mirdametinib for NF1 plexiform neurofibromas; Merck KGaA acquired it in 2025.
Overview
SpringWorks Therapeutics, based in Stamford, Connecticut, developed nirogacestat, the first approved treatment for desmoid tumours, and mirdametinib for NF1 plexiform neurofibromas, and Merck KGaA completed its acquisition of the company for around 3.9 billion dollars in 2025. Nirogacestat, sold as Ogsiveo, was approved in November 2023 on the DeFi trial, and mirdametinib, sold as Gomekli, in February 2025. OnCo links it to desmoid tumour and sarcomas, to both drug records, and to the bottleneck of rare and paediatric cancers without markets, which its two products show can be overcome. Whether a large pharma keeps investing in rare-tumour indications of this size is the open question after the acquisition. Nirogacestat and mirdametinib have their own pages.
Headquarters
Stamford, CT, US
Scorecard
All companies#170of 1244 companies, score 33
- approved products +12
- targets +2
- modalities +2
- regions +3
- 24-month regulatory events +2
- registry trials +12
2 approved, 0 in phase 3, 0 earlier, 1 targets, 37 registry studies. Formula on the scorecards page.
Deals
Deal map| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2025-04-28 | SpringWorks Therapeutics (Merck KGaA) to Merck KGaA Nirogacestat (Ogsiveo) and mirdametinib (Gomekli) | Acquisition | not disclosed | $3.9bn | source |
Type
Website
ApprovedSmall-molecule gamma-secretase inhibitor
Nirogacestat · Ogsiveo
Nirogacestat is the first approved medicine for desmoid tumours, locally invasive growths that do not spread but can be crippling; it works by blocking Notch signalling.
ApprovedSmall-molecule allosteric MEK1/2 inhibitor
Mirdametinib · Gomekli / Ezmekly
Mirdametinib (Gomekli in the US, Ezmekly in Europe) is a MEK-blocking capsule or dispersible tablet for adults and children with neurofibromatosis type 1 whose plexiform neurofibromas cannot be removed surgically; it is the first such drug approved for adults.
Similar pages
- IdeaIntermittent or stop-and-restart nirogacestat in desmoid tumours
Shares DeFi, Nirogacestat, Desmoid tumour, Sarcomas (soft tissue, bone, GIST).
- TrialA Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Shares Nirogacestat, Merck KGaA (EMD Serono), Desmoid tumour.
- TechnologyGamma-secretase inhibitors
Shares DeFi, Nirogacestat, Sarcomas (soft tissue, bone, GIST).
- TargetGamma-secretase (PSEN1)
Shares Nirogacestat, Desmoid tumour.
- IdeaOne legal framework for pooling rare cancer data across borders
Shares Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- IdeaLet adolescents from age 12 into adult trials when the cancer biology is the same
Shares Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- IdeaA funded expert second opinion for every new high-stakes or rare cancer diagnosis
Shares Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- IdeaMandatory national virtual tumour boards for rare and complex cancers
Shares Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
cancers
fronts
drugs
ApprovedSmall-molecule allosteric MEK1/2 inhibitor
Mirdametinib · Gomekli / Ezmekly
ApprovedSmall-molecule gamma-secretase inhibitor
Nirogacestat · Ogsiveo